Pulmonary Vasodilators. Part 1

Vasodilatadores pulmonares Parte 1

Published 2013-06-20

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 25 No. 2 (2013)
Section
Topics review
How to Cite
Pulmonary Vasodilators. Part 1.
rev. colomb. neumol. [Internet]. 2013 Jun. 20 [cited 2024 Nov. 24];25(2). Disponible en: https://doi.org/10.30789/rcneumologia.v25.n2.2013.119
DOI

https://doi.org/10.30789/rcneumologia.v25.n2.2013.119
Dimensions
PlumX
license

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Clara Patricia García, MD.
Clínica Universitaria Bolivariana. Hospital Pablo Tobón Uribe. Fundación Antioqueña de Infectología. Medellín, Colombia.
    Show authors biography

    Clara Patricia García, MD.,

    Internista, Neumóloga. Clínica Universitaria Bolivariana. Hospital Pablo Tobón Uribe. Fundación Antioqueña de Infectología. Medellín, Colombia.

    Pulmonary vasodilators are drugs which are currently used in the management of patients with pulmonary arterial hypertension. They have been introduced over the last few years, and many of them are already available in Colombia. However, the advent of these therapies demands a deeper knowledge of their actions, potential interactions, mechanisms of action, and adverse effects, as well as the benefits which have been demostrated in several clinical trials, so that the physician is able to make the best choice for each individual suffering from this disease according to group, comorbidities, and functional class, as well as to teach both the physician and the patient to recognize their potential adverse events.

    Article visits 1143 | PDF visits 6410

    Downloads

    Download data is not yet available.
    1. Darius H, Hossmann V, Schrör K. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study. Klin Wochenschr. 1986;64:545-51.
    2. J ohnson EJ, Mackie IJ, Machin SJ, Brozović B. Preservation of platelet function in cryopreserved platelet concentrates with prostacyclin. Clin Lab Haemat. 1984;6:141-4.
    3. Gomberg M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur Respir J. 2008;31:891-901.
    4. Monografía Ventavis®
    5. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Circulation 1982;66:334-8.
    6. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477-82.
    7. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-78.
    8. Olschewski H, Walmrath D, Schermuly R, Ghofrani HA, Grimminger F, Seeger W. Aerosolised prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996;124:820-4.
    9. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med. 2000;132:435-43.
    10. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.
    11. Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest. 2003;124:1294-304.
    12. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-63.
    13. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 2005;26:1895-1902.
    14. Wilkens H et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001;104:1218-22.
    15. Ghofrani HA, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003; 41:158-164.
    16. Galie N, Humbert M, Vachie´ry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, doubleblind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496-1502.
    17. Ono F, Nagaya N, Okumura H, ShimizuY, Kyotani S, Nakanishi N, et al. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest. 2003;123:1583-88.
    18. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800-4.
    19. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006;129:683-688.
    20. Voswinckel R, Enke B, Reichenberger F, et al. Favourable effects of inhaled treprostinil in severe pulmonary hypertension. J Am Coll Cardiol. 2006;48:1672-1681.
    21. Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hipertensión therapy. Eur Respir Rev. 2009;18:35-41.
    22. Ghofrani HA, Weimann G, Frey R, et al. BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension. BMC Pharmacology. 2007;7:S8.
    23. Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009;33:785-92.
    24. Ghofrani HA, Weimann G, Frey R, et al. BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension. BMC Pharmacology. 2007;7:S8.
    25. Archer S, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension, N Engl J Med. 2009;361:1864-71.
    26. Muirhead GJ, Rance DJ, Walker DK, Wastall P. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate. Br J Clin Pharmacol. 2002;53:13S-20S.
    27. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko R, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61:280-288.
    28. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-57.
    29. Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2007;30:922-7.
    30. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894-903.
    31. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-22.
    32. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42:158-64.
    33. Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol. 2005;96: 1334-6.
    34. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149:521-30.
    35. Archer S, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361:1864-71.
    36. Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis. Clinical Research Network. N Engl J Med. 2010;363:620-628.
    37. GlaxoSmithKline. Ficha Técnica Flolan®. Marzo 2007.

    Information

    Journal history

    Keywords

    QR code

    Funding

    Support + Info: Here

     

     

    Directories and indexes

    Google Scholar profile

    Most read in the last 30 days

    Current Issue

    Sistema OJS 3.4.0.7 - Metabiblioteca |